Learning the lessons of antitumour necrosis factor therapy-associated psoriasis.
暂无分享,去创建一个
[1] W. Dixon,et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register , 2008, Annals of the rheumatic diseases.
[2] R. Panaccione,et al. Hepatosplenic T cell lymphoma in inflammatory bowel disease , 2008, Gut.
[3] J. S. Henning,et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. , 2008, Arthritis and rheumatism.
[4] F. Aubin,et al. Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy. , 2008, Joint, bone, spine : revue du rhumatisme.
[5] A. Zinsmeister,et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. , 2008, Gastroenterology.
[6] J. Carter,et al. Psoriasiform lesions induced by tumour necrosis factor antagonists: a skin-deep medical conundrum , 2008, Annals of the rheumatic diseases.
[7] K. Reich,et al. Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases , 2008, Archives of Dermatological Research.
[8] P. Rutgeerts,et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study , 2007, Gut.
[9] B. Thiers. Psoriasis and Pustular Dermatitis Triggered by TNF-α Inhibitors in Patients With Rheumatologic Conditions , 2008 .
[10] G. Haroske,et al. Tumor Necrosis Factor-α Inhibitor-Induced Psoriasis or Psoriasiform Exanthemata , 2008 .
[11] G. Haroske,et al. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. , 2008, American journal of clinical dermatology.
[12] S. Lepreux,et al. Psoriasiform Eruptions During Anti–TNF-α Treatment: Psoriasis or Not? , 2007 .
[13] L. Fry,et al. Triggering psoriasis: the role of infections and medications. , 2007, Clinics in dermatology.
[14] S. Lepreux,et al. Psoriasiform eruptions during anti TNF-alpha treatment: psoriasis or not? , 2007, Archives of dermatology.
[15] A. Taïeb,et al. Psoriasiform drug eruptions under anti-TNF treatment of arthritis are not true psoriasis. , 2007, Acta dermato-venereologica.
[16] W. Sandborn,et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[17] R. Inman,et al. Early cytokine profiles in the joint define pathogen clearance and severity of arthritis in Chlamydia-induced arthritis in rats. , 2006, Arthritis and rheumatism.
[18] G. Lichtenstein. Progressive Multifocal Leukoencephalopathy After Natalizumab Therapy for Crohn's Disease , 2006 .
[19] U. Kajermo,et al. Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor‐α in the normal palmar eccrine sweat duct? , 2005, The British journal of dermatology.
[20] A. Silman,et al. The British Society for Rheumatology Biologics Register , 2005, Annals of the rheumatic diseases.
[21] O. Boyman,et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-α production , 2005, The Journal of experimental medicine.
[22] V. Pascual,et al. Cross-regulation of TNF and IFN-¿ in autoimmune diseases , 2005 .
[23] I. Elefsiniotis,et al. Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B. , 2005, European journal of dermatology : EJD.
[24] V. Pascual,et al. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[25] A. Gottlieb,et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. , 2004, Journal of the American Academy of Dermatology.
[26] E. Fonseca,et al. Psoriasiform Eruption Induced by Infliximab , 2004, The Annals of pharmacotherapy.
[27] D. Baeten,et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? , 2003, Annals of the rheumatic diseases.
[28] J. Keane,et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. , 2001, The New England journal of medicine.
[29] M. Wiselka,et al. Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis C , 2000, Postgraduate medical journal.
[30] M. Gumbs,et al. Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis , 2000 .
[31] H. Mcdevitt,et al. The role of TNFα and related cytokines in the development and function of the autoreactive T-cell repertoire , 1997 .
[32] G. Watkinson,et al. Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis , 1982, The British journal of dermatology.